Gamida Cell

Gamida Cell

Biotechnology, 116 Huntington Ave, Boston, Massachusetts, 02116, United States, 51-200 Employees

gamida-cell.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is GAMIDA CELL

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their i...

Read More

map
  • 116 Huntington Ave, Boston, Massachusetts, 02116, United States Headquarters: 116 Huntington Ave, Boston, Massachusetts, 02116, United States
  • 1998 Date Founded: 1998
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541720 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GAMIDA CELL

Gamida Cell Org Chart and Mapping

Employees

Nick Bayrakdarian

Vice President, Us Cell Therapy Operations

Sheila Ouverson

Regional Account Manager

Ornit Bergman

QA Director Supply Chain

Ashley Engemann

Medical Science Liaison - East

Paul Catanzaro

Region Account Director

Heayoung Shin

Senior Director Medical Affairs

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Gamida Cell

Answer: Gamida Cell's headquarters are located at 116 Huntington Ave, Boston, Massachusetts, 02116, United States

Answer: Gamida Cell's phone number is 61********

Answer: Gamida Cell's official website is https://gamida-cell.com

Answer: Gamida Cell's revenue is $25 Million to $50 Million

Answer: Gamida Cell's SIC: 2836

Answer: Gamida Cell's NAICS: 541720

Answer: Gamida Cell has 51-200 employees

Answer: Gamida Cell is in Biotechnology

Answer: Gamida Cell contact info: Phone number: 61******** Website: https://gamida-cell.com

Answer: Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer. Our stem cell transplant therapy was approved by the US FDA in April 2023. Clinical study of our NK cell therapy candidate GDA-201 is ongoing.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access